Wilder-Smith C H, Schimke J, Osterwalder B, Senn H J
Department of Medicine C, Kantonspital, St. Gallen, Switzerland.
Acta Oncol. 1991;30(6):731-4. doi: 10.3109/02841869109092448.
The antiemetic efficacy of cinnarizine was assessed in 17 cancer patients receiving platin-based chemotherapy (cisplatin dose-range 30-160 mg, or carboplatin 270-600 mg) in a randomised, cross-over study. The patients were prophylactically given oral metoclopramide 3 x 1 mg/kg and lorazepam 2 x 1 mg with or without cinnarizine 3 x 75 mg. The antiemetic combination with cinnarizine prevented emesis completely on 51% of 35 days with chemotherapy and less than 3 emetic episodes occurred on 86% of the days, compared with 43% and 57% (p less than 0.01) without cinnarizine respectively. Severe nausea was significantly less frequent with cinnarizine and 59% of the chemotherapy days were without nausea, compared to 46% of the days without cinnarizine (p less than 0.05). Side-effects were uncommon and minor with both antiemetic regimens. The study suggests that addition of cinnarizine to metoclopramide and lorazepam improves antiemetic prophylaxis in low to medium dose platin-based chemotherapy.
在一项随机交叉研究中，对17名接受铂类化疗（顺铂剂量范围为30 - 160毫克，或卡铂270 - 600毫克）的癌症患者评估了桂利嗪的止吐疗效。患者预防性口服甲氧氯普胺3×1毫克/千克和劳拉西泮2×1毫克，同时服用或不服用桂利嗪3×75毫克。与未使用桂利嗪时分别为43%和57%的情况相比，含桂利嗪的止吐组合在35天化疗期间有51%的时间完全预防了呕吐，且86%的天数呕吐发作少于3次（p < 0.01）。使用桂利嗪时严重恶心的发生频率显著降低，59%的化疗日无恶心，而未使用桂利嗪时这一比例为46%（p < 0.05）。两种止吐方案的副作用均不常见且轻微。该研究表明，在甲氧氯普胺和劳拉西泮的基础上加用桂利嗪可改善低至中剂量铂类化疗的止吐预防效果。
